WHIPPANY, N.J. and MORRIS PLAINS, N.J., April 14, 2016 /CNW/ -- ExxPharma Therapeutics LLC ("ExxPharma") and Halo Pharmaceutical Inc. ("Halo") have entered into a collaboration agreement to develop and manufacture drug products for customers of Halo and ExxPharma using ExxPharma's innovative drug delivery systems and twin screw extrusion-based manufacturing technology. ExxPharma will be responsible for technical development while Halo will have overall responsibility of drug product manufacturing and quality control at Halo's state-of-the art GMP-compliant manufacturing facility in Whippany, NJ.
Twin screw extrusion is a highly versatile and precisely-controlled continuous manufacturing process that utilizes small mass mixing to improve efficiency, maximize quality and reduce cost. The technology, while relatively new to the pharmaceutical industry, has been gaining wide acceptance especially with hot melt extrusion (HME) which ExxPharma and others have used effectively to improve the bioavailability of poorly soluble drug substances.
"Collaborating with Halo offers us the opportunity to serve our clients more efficiently using fully-integrated, cost-effective complementary services that encompass formulation/process feasibility studies, Phase I to Phase III clinical development and commercial production," said Isaac Ghebre-Sellassie, Founder and President of ExxPharma, which is based in Morris Plains, NJ. "Halo has an impressive track record of manufacturing clinical trial material and commercial drug products both for U.S. and European markets. This collaboration allows us to seamlessly transfer analytical and manufacturing technologies from a research and development environment at ExxPharma to a GMP compliant manufacturing facility."
"We are excited about this collaboration with ExxPharma as it allows us to provide an alternative technology to our customers," said Lee Karras, CEO of Halo. "Further, Isaac is a preeminent scientist in this field and having his guidance will be a tremendous asset for our customers who may face challenges with bioavailability or even want to pursue abuse deterrent technologies which HME can potentially provide," Mr. Karras went on to say.
ABOUT HALO PHARMACEUTICAL
Halo Pharmaceutical is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise as well as a wide spectrum of manufacturing services from its locations in Whippany, New Jersey USA and Montreal, Quebec Canada to its international client base. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharmaceutical's capabilities in the areas of tech transfer, process and product development, production, scale-up/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information please contact email@example.com.
ABOUT EXXPHARMA THERAPEUTICS
ExxPharma Therapeutics ("ExxPharma") is a New Jersey-based pharmaceutical development company that provides value-added formulation/process development services to pharmaceutical companies using innovative drug delivery systems and twin screw/hot melt extrusion manufacturing technologies with a focus on solubility/bioavailability enhancement (BCS Class II and IV compounds), modified release technology, abuse deterrent formulations, taste-masking and fixed dose combination products. Development candidates include new chemical entities, enhancements of approved products and specialty generics. ExxPharma's staff has over 30 years of combined experience in twin screw/hot melt extrusion processing technologies.
SOURCE Halo Pharmaceutical
For further information: Halo Pharmaceutical, Manu Jetley, Vice President, P. 973.428.4310, F. 973.428.4017, firstname.lastname@example.org, ExxPharma Therapeutics, Hibre Terefe, Vice President, R & D, P. 908-231-1819, F. 908-231-1814, email@example.com, http://www.halopharma.com